Cambridge Investment Research Advisors, Inc. Arrowhead Pharmaceuticals, Inc. Transaction History

Cambridge Investment Research Advisors, Inc.

  • $32.9 Billion
  • Q2 2025

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 02, 2021
SELL
$58.38 - $84.96 $188,567 - $274,420
-3,230 Closed
0 $0
Q2 2021

Aug 10, 2021
BUY
$62.15 - $90.32 $200,744 - $291,733
3,230 New
3,230 $267,000
Q1 2021

May 07, 2021
SELL
$61.35 - $90.47 $163,681 - $241,373
-2,668 Closed
0 $0
Q4 2020

Feb 04, 2021
BUY
$43.82 - $85.37 $116,911 - $227,767
2,668 New
2,668 $204,000
Q1 2018

May 09, 2018
SELL
$3.72 - $7.64 $39,432 - $80,984
-10,600 Closed
0 $0
Q2 2017

Aug 08, 2017
BUY
N/A
10,600
10,600 $17,000

Others Institutions Holding ARWR

# of Institutions
321
Shares Held
99.1M
Call Options Held
444K
Put Options Held
568K
View Full List

About ARROWHEAD PHARMACEUTICALS, INC.

ARWR Quotes by TradingView
  • Ticker ARWR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 105,849,000
  • Market Cap $3.97B
  • Description
  • Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...
More about ARWR
Track This Portfolio

Track Cambridge Investment Research Advisors, Inc. Portfolio

Follow Cambridge Investment Research Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cambridge Investment Research Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Cambridge Investment Research Advisors, Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email